PROMISE: Percutaneous peRipheral cannulatiOn for Minimally-InvaSive Heart Valve surgEry
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart Valve Diseases
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Access site related vascular complications.
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
In addition to conventional heart valve surgery (HVS) via full-sternotomy, which is still the most prevalent therapeutic strategy to address valvular heart disease (VHD), minimally-invasive approaches evolved as safe alternatives, resulting in lower postoperative ventilation times, transfusion rates and shorter in-hospital stay. Femoral artery cannulation is traditionally performed via surgical cutdown to establish cardiopulmonary bypass during minimally-invasive HVS. To avoid groin incision associated infection and lymphocele formation, and further minimize surgical trauma, the use of percutaneous cannulation including novel endovascular closure devices increases as an alternative but remains to be investigated.
The Percutaneous peRipheral cannulatiOn for Minimally-InvaSive heart valve surgEry (PROMISE) registry aims to elucidate the safety, feasibility, and effectiveness of newly developed vascular closure devices during minimally-invasive HVS. Acute intra- and perioperative complications will be evaluated according to modified definitions of the Valve Academic Research Consortium (VARC)-3. In addition, based on the initial results, the comparison of percutaneous cannulation with conventional surgical cut-down techniques is planned.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Retrospective analysis of all patients undergoing minimally-invasive heart valve surgery using novel endovascular closure devices for percutaneous cannulation within 6 high-volume heart valve centres in Germany.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Access site related vascular complications.
Time Frame: Date of operation (day 0) until 30 days after operation (day 30).
Incidence (number of) of access site related vascular complications, according to modified Valve Academic Research Consortium 3 (VARC 3) criteria.
Cardiovascular mortality.
Time Frame: Date of operation (day 0) until 30 days after operation (day 30).
Incidence (number of) of cardiovascular death, defined as death attributable to myocardial ischemia and infarction, heart failure, cardiac arrest because of other or unknown cause, or cerebrovas-cular accident.
All-cause mortality.
Time Frame: Date of operation (day 0) until 30 days after operation (day 30).
Incidence (number of) of death from any cause.